Prostate Cancer Detection with Multiparametric MRI: A Comparison of 1 M-Concentration Gadobutrol with 0.5 M-Concentration Gadolinium-Based Contrast Agents | Zendy

Takeshi Hara | Zendy; Takeshi Ogata | Zendy; Hiroko Wada | Zendy; Takayuki Yabuki | Zendy; Susumu Kanazawa | Zendy

Open Access

Prostate Cancer Detection with Multiparametric MRI: A Comparison of 1 M-Concentration Gadobutrol with 0.5 M-Concentration Gadolinium-Based Contrast Agents

Author(s) -

Takeshi Hara,

Takeshi Ogata,

Hiroko Wada,

Takayuki Yabuki,

Susumu Kanazawa

Publication year - 2018

Publication title -

current urology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.476

H-Index - 13

eISSN - 1661-7657

pISSN - 1661-7649

DOI - 10.1159/000447219

Subject(s) - gadobutrol , gadolinium , medicine , magnetic resonance imaging , prostate cancer , nuclear medicine , contrast (vision) , radiology , prostate , cancer , chemistry , organic chemistry , artificial intelligence , computer science

Gadobutrol (Gd-DO3A-butrol) (Gadovist®) is a macrocyclic gadolinium-based contrast agent for magnetic resonance imaging (MRI) formulated at 1.0 mmol Gd/ml. Gadobutrol's higher concentration compared to other contrast agents (0.5 mmol Gd/ml) is associated with higher T1 relaxivity. We examined whether gadobutrol increases the accuracy of prostate cancer detection using dynamic contrast-enhanced MRI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research